Navigation Links
Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients
Date:5/16/2008

s/pubs/pdf/kdd.pdf. Accessed

April 24, 2008.


'/>"/>
SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Pharmacopeia Announces Upcoming Late-Breaker Presentation of Phase 2a Results for Its First-in-Class Investigational DARA Compound, PS433540
2. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
3. Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus
4. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
5. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
6. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
7. Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
8. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
9. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
10. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
11. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference 2Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference 3Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference 4FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 2FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 3Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 2Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 3Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 4Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 5Genomes of biofuel yeasts reveal clues that could boost fuel ethanol production worldwide 14759 1Genomes of biofuel yeasts reveal clues that could boost fuel ethanol production worldwide 14759 2Catholics for Choice Statement on Healthcare Reform Bill 60931 1Catholics for Choice Statement on Healthcare Reform Bill 60931 2Findings show nanomedicine promising for treating spinal cord injuries 10653 1Findings show nanomedicine promising for treating spinal cord injuries 10653 2Findings show nanomedicine promising for treating spinal cord injuries 10653 3
Other Medicine News:Health News:Contamination from depleted uranium found in urine 20 years later 2Health News:Red Cross Receives $250,000 From Wal-Mart to Assist With Southern California Wildfire Relief Efforts 2Health News:Red Cross Receives $250,000 From Wal-Mart to Assist With Southern California Wildfire Relief Efforts 3Health News:Marital Stress Linked to Heart Disease 2Health News:Marital Stress Linked to Heart Disease 3Health News:Young Innovations, Inc. Announces Results for the Third Quarter Ended September 30, 2007 and Declares Quarterly Dividend 2Health News:Young Innovations, Inc. Announces Results for the Third Quarter Ended September 30, 2007 and Declares Quarterly Dividend 3Health News:Young Innovations, Inc. Announces Results for the Third Quarter Ended September 30, 2007 and Declares Quarterly Dividend 4Health News:Young Innovations, Inc. Announces Results for the Third Quarter Ended September 30, 2007 and Declares Quarterly Dividend 5Health News:Young Innovations, Inc. Announces Results for the Third Quarter Ended September 30, 2007 and Declares Quarterly Dividend 6Health News:Susan G. Komen For The Cure, Karmanos Cancer Institute, Local Hospitals Call on Policymakers to Address Injustice and Unfairness in Breast Cancer Incidence and Mortality 2Health News:Susan G. Komen For The Cure, Karmanos Cancer Institute, Local Hospitals Call on Policymakers to Address Injustice and Unfairness in Breast Cancer Incidence and Mortality 3Health News:Susan G. Komen For The Cure, Karmanos Cancer Institute, Local Hospitals Call on Policymakers to Address Injustice and Unfairness in Breast Cancer Incidence and Mortality 4